MCID: VSC018
MIFTS: 32

Visceral Steatosis

Categories: Liver diseases, Rare diseases

Aliases & Classifications for Visceral Steatosis

MalaCards integrated aliases for Visceral Steatosis:

Name: Visceral Steatosis 20 54
Fatty Metamorphosis of Viscera 20 70
Fatal Neonatal Hepatic Steatosis 20
White Liver Disease 20
Steatosis of Liver 20
Steatohepatitis 70

Classifications:



External Ids:

UMLS 70 C0341447 C2711227

Summaries for Visceral Steatosis

MalaCards based summary : Visceral Steatosis, also known as fatty metamorphosis of viscera, is related to hypoglycemia and visceral steatosis, congenital. An important gene associated with Visceral Steatosis is SLC22A5 (Solute Carrier Family 22 Member 5), and among its related pathways/superpathways are AMP-activated Protein Kinase (AMPK) Signaling and Fatty Acyl-CoA Biosynthesis. The drugs Selenium and Exenatide have been mentioned in the context of this disorder. Affiliated tissues include liver, endothelial and skeletal muscle.

Related Diseases for Visceral Steatosis

Graphical network of the top 20 diseases related to Visceral Steatosis:



Diseases related to Visceral Steatosis

Symptoms & Phenotypes for Visceral Steatosis

Drugs & Therapeutics for Visceral Steatosis

Drugs for Visceral Steatosis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 200)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Selenium Approved, Investigational, Vet_approved Phase 4 7782-49-2
2
Exenatide Approved, Investigational Phase 4 141758-74-9 15991534
3
Orlistat Approved, Investigational Phase 4 96829-58-2 3034010
4
Metformin Approved Phase 4 657-24-9 14219 4091
5
Alogliptin Approved Phase 4 850649-61-5 11450633
6
Dulaglutide Approved, Investigational Phase 4 923950-08-7
7
Rifaximin Approved, Investigational Phase 4 80621-81-4 6436173 46783403
8
Folic acid Approved, Nutraceutical, Vet_approved Phase 4 59-30-3 6037
9
Methionine Approved, Nutraceutical Phase 4 63-68-3 6137
10 Folate Phase 4
11 Vitamin B Complex Phase 4
12 Alpha-lipoic Acid Phase 4
13 Thioctic Acid Phase 4
14 Vitamin B9 Phase 4
15 Lipid Regulating Agents Phase 4
16 Anti-Obesity Agents Phase 4
17 Glucagon-Like Peptide 1 Phase 4
18 insulin Phase 4
19 Insulin, Globin Zinc Phase 4
20 Anti-Bacterial Agents Phase 4
21 Gastrointestinal Agents Phase 4
22
Liraglutide Approved Phase 3 204656-20-2 44147092
23
tannic acid Approved Phase 3 1401-55-4
24
Benzocaine Approved, Investigational Phase 3 1994-09-7, 94-09-7 2337
25
Losartan Approved Phase 3 114798-26-4 3961
26
Angiotensin II Approved, Investigational Phase 3 68521-88-0, 4474-91-3, 11128-99-7 172198
27
Mineral oil Approved, Vet_approved Phase 3 8042-47-5
28 Raspberry Approved Phase 2, Phase 3
29
Chromium Approved Phase 2, Phase 3 7440-47-3 27668
30
Iron Approved Phase 2, Phase 3 7439-89-6 23925 29936
31
Levoleucovorin Approved, Investigational Phase 2, Phase 3 68538-85-2 149436
32
Hydroxocobalamin Approved Phase 2, Phase 3 13422-51-0 11953898 15589840
33
Potassium citrate Approved, Investigational, Vet_approved Phase 2, Phase 3 866-84-2
34
Copper Approved, Investigational Phase 2, Phase 3 7440-50-8 27099
35
Sodium citrate Approved, Investigational Phase 2, Phase 3 68-04-2
36
Molybdenum Approved Phase 2, Phase 3 7439-98-7 185498
37
carbamide peroxide Approved Phase 2, Phase 3 124-43-6
38
Calcium carbonate Approved, Investigational Phase 2, Phase 3 471-34-1
39
Iodine Approved, Investigational Phase 2, Phase 3 7553-56-2 807
40
chenodeoxycholic acid Approved Phase 3 474-25-9 10133
41
Ethanol Approved Phase 3 64-17-5 702
42
Rimonabant Approved, Investigational Phase 3 168273-06-1, 158681-13-1 104850
43
Choline Approved, Nutraceutical Phase 3 62-49-7 305
44
Citric acid Approved, Nutraceutical, Vet_approved Phase 2, Phase 3 77-92-9 311
45
Manganese Approved, Nutraceutical Phase 2, Phase 3 7439-96-5 27854
46
Pantothenic acid Approved, Nutraceutical, Vet_approved Phase 2, Phase 3 79-83-4 6613
47
Betaine Approved, Nutraceutical Phase 2, Phase 3 107-43-7, 6915-17-9 248
48
Vitamin A Approved, Nutraceutical, Vet_approved Phase 2, Phase 3 68-26-8, 11103-57-4 445354
49
Inulin Approved, Investigational, Nutraceutical Phase 2, Phase 3 9005-80-5 24763
50
Cyanocobalamin Approved, Nutraceutical Phase 2, Phase 3 68-19-9 44176380

Interventional clinical trials:

(show top 50) (show all 329)
# Name Status NCT ID Phase Drugs
1 A Randomised Controlled Trial of Lifestyle Versus Ezetimibe Plus Lifestyle in Patients With Non-alcoholic Steatohepatitis Unknown status NCT01950884 Phase 4 Ezetimibe
2 NAFLD in T2DM: Prevalence in Hispanics and Role of Treatment Completed NCT01002547 Phase 4 pioglitazone-placebo;pioglitazone;pioglitazone-placebo;Vitamin E-placebo
3 Biochemical and Echosonographic Impacts Using Siliphos-Selenium-Methionine-Alpha Lipoic Acid + Metformin Versus Metformin in Patients With Fatty Liver and Steatohepatitis Completed NCT01650181 Phase 4 Metformin;Metformin
4 Long-term Role of Pioglitazone in Non-Alcoholic Fatty Liver Disease (NAFLD) in Type 2 Diabetes Mellitus (T2DM). Completed NCT00994682 Phase 4 Pioglitazone study drug;Placebo;Pioglitazone Open Label
5 Role of Pioglitazone in the Treatment of Non-alcoholic Steatohepatitis (NASH) Completed NCT00227110 Phase 4 Pioglitazone;Placebo
6 Clinical Study Evaluating the Efficacy and Safety of Montelukast in the Treatment of Non-Alcoholic Steatohepatitis (NASH) Completed NCT04537780 Phase 4 Montelukast
7 Effects of Exenatide (Byetta®) on Biochemical and Histological Parameters of Liver Function in Patients With Nonalcoholic Steatohepatitis (NASH) Completed NCT01208649 Phase 4 Exenatide
8 Orlistat (Xenical) in the Treatment of Overweight Patients With Nonalcoholic Steatohepatitis (NASH) Completed NCT00160407 Phase 4 Orlistat (Xenical)
9 To Evaluate the Effect of Nesinaact on Non-alcoholic Steatohepatitis Through MRI and Liver Fibroscan in Patients With Type 2 Diabetes: A Prospective, Open-Label, Single-Arm, Single-Center Clinical Study Recruiting NCT03950505 Phase 4 Nesinaact 25/15 (Alogliptin benzoate 25mg, pioglitazone hydrochloride 15mg) treatment for 24 weeks
10 Efficacy and Safety of Berberine in Non-alcoholic Steatohepatitis: a Multicentre, Randomised, Placebo-controlled Trial Recruiting NCT03198572 Phase 4 Placebo;Berberine
11 A Multicentre Controlled and Randomized Study Assessing the Effect of Dulaglutide add-on to Dietary Reinforcement Versus Dietary Reinforcement Alone in Patients With Type 2 Diabetes and Carriers of a Non-alcoholic Steatohepatitis Not yet recruiting NCT03648554 Phase 4 dulaglutide (TRULICITY®) 1.5 mg
12 RiFL: Rifaximin in Fatty Liver Disease. Does Modulation of Gut Microbiota Reduce Hepatic Inflammation in Non-Alcoholic Steatohepatitis (NASH)? Terminated NCT01355575 Phase 4 Rifaximin
13 The Effect of Synbiotics Supplement on Lipid Profile, Liver Enzymes, Inflammatory Factors and Hepatic Fibrosis in Lean and Normal Weight Patients With Nonalcoholic Fatty Liver Unknown status NCT02530138 Phase 2, Phase 3
14 Comparing Effects of Liraglutide and Bariatric Surgery on Weight Loss, Liver Function, Body Composition, Insulin Resistance, Endothelial Function and Biomarkers of Non-alcoholic Steatohepatitis (NASH) in Obese Asian Adults Unknown status NCT02654665 Phase 3 Liraglutide
15 Clinical Research Network in Nonalcoholic Steatohepatitis: Pioglitazone vs. Vitamin E vs. Placebo for the Treatment of Non-Diabetic Patients With Nonalcoholic Steatohepatitis (PIVENS) Completed NCT00063622 Phase 3 Pioglitazone;Matching placebo
16 Omega 3 Fish Oil Supplements vs. Placebo for Patients With Non-alcoholic Steatohepatitis (NASH) Completed NCT00681408 Phase 2, Phase 3 Omega 3 Fish Oil supplements;Placebo
17 Efficacy and Safety of Viusid, a Nutritional Supplement, in Patients With Nonalcoholic Steatohepatitis. A Randomized, Controlled and Open Label Study Completed NCT00509418 Phase 3
18 Efficacy and Safety of Diamel, a Nutritional Supplement, in Patients With Nonalcoholic Steatohepatitis. A Randomized and Double Blind Controlled Study Completed NCT00820651 Phase 3
19 A Randomised, Controlled Trial of Losartan as an Anti-fibrotic Agent in Non-alcoholic Steatohepatitis Completed NCT01051219 Phase 3 Losartan
20 The Effect of Pentoxifylline on Nonalcoholic Steatohepatitis (NASH) Completed NCT00267670 Phase 2, Phase 3 Pentoxifylline;Placebo
21 The Effects of Flaxseed Supplement on Lipid Profile, Liver Enzymes, Inflammatory Factors and Hepatic Fibrosis in Patients With Nonalcoholic Fatty Liver Disease Completed NCT02395900 Phase 2, Phase 3
22 The Effects of Synbiotics Supplement on Lipid Profile, Liver Enzymes, Inflammatory Factors and Hepatic Fibrosis in Patients With Nonalcoholic Steatohepatitis Completed NCT01791959 Phase 2, Phase 3
23 A Phase IIb, Double Blind Randomized, Controlled Clinical Trial, to Evaluate the Efficacy and Safety of Two Aramchol Doses Versus Placebo in Patients With Non-Alcoholic Steatohepatitis (NASH) - Aramchol 005 Study Completed NCT02279524 Phase 2, Phase 3 Aramchol
24 S-Adenosylmethionine Therapy for Non-Alcoholic Steatohepatitis Completed NCT00108589 Phase 3 S-adenosylmethionine
25 Open-label, Randomized, Parallel-Group, Exploratory Study to Investigate the Effects of Different Doses of S-adenosyl-L-methionine (SAMe) in Subjects With Nonalcoholic Steatohepatitis (NASH) and Non-treated Matched Healthy Volunteers as Control Group Completed NCT01754714 Phase 3 SAMe 1000 mg;SAMe 1500 mg;SAMe 2000 mg
26 Study of Efficacy and Tolerance of Treatment With DHA, Choline and Vitamin E in Children With Non-alcoholic Steatohepatitis Completed NCT01934777 Phase 3 Docosahexaenoic Acid plus Vitamin E plus choline;placebo pearls
27 The Effects of Resveratrol Supplement on Lipid Profile, Liver Enzymes, Inflammatory Factors and Hepatic Fibrosis in Patients With Nonalcoholic Steatohepatitis Completed NCT02030977 Phase 2, Phase 3
28 Polyunsaturated Fatty Acid (Pufa) Omega 3 in the Reduction of the Inflammatory Component of the Nonalcoholic Steatohepatitis (Nash):Randomized Placebo Controlled Study Completed NCT01992809 Phase 3
29 Clinical Research Network in Nonalcoholic Steatohepatitis: Treatment of Nonalcoholic Fatty Liver Disease in Children (TONIC) Completed NCT00063635 Phase 3 Metformin;Matching placebo
30 Development and Evaluation of the Effectiveness of Complex Therapy of Steatohepatitis of Various Aetiologies Based on Metabolomic Analysis With the Use of Innovative Medical Nutrition Products Recruiting NCT04308980 Phase 2, Phase 3
31 Efficacy and Safety of Dapagliflozin in Non-alcoholic Steatohepatitis: a Multicentre, Randomized, Placebo-controlled Trial Recruiting NCT03723252 Phase 3 Dapagliflozin;Placebo
32 A Phase 3, Multinational, Multicenter, Randomized, Double-Blind, Placebo-Controlled Clinical Study to Evaluate the Efficacy and Safety of Aramchol in Subjects With Nonalcoholic Steatohepatitis (NASH) With Open-Label Part to Evaluate the Safety, PK and Treatment Response Kinetics of Aramchol. The ARMOR Study Recruiting NCT04104321 Phase 3 Aramchol;Placebo
33 A Phase 3, Multinational, Double-Blind, Randomized, Placebo-Controlled Study of MGL-3196 (Resmetirom) in Patients With Non-Alcoholic Steatohepatitis (NASH) and Fibrosis to Resolve NASH and Reduce Progression to Cirrhosis and/or Hepatic Decompensation Recruiting NCT03900429 Phase 3 MGL-3196;Placebo
34 An Investigator Initiated Prospective, Four Arms Randomized Comparative Study of Efficacy and Safety of Saroglitazar, Vitamin E and Life Style Modification in Patients With Nonalcoholic Fatty Liver Disease (NAFLD)/ Non-alcoholic Steatohepatitis (NASH) Recruiting NCT04193982 Phase 3 Saroglitazar;Vitamin E;Combination drug
35 A Phase 3, Double-Blind, Randomized, Long-Term, Placebo-Controlled, Multicenter Study Evaluating the Safety and Efficacy of Obeticholic Acid in Subjects With Nonalcoholic Steatohepatitis Active, not recruiting NCT02548351 Phase 3 Obeticholic Acid;Placebo
36 A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Obeticholic Acid in Subjects With Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis Active, not recruiting NCT03439254 Phase 3 Obeticholic acid (10 mg);Obeticholic acid (10 mg to 25 mg);Placebo
37 The Effect of Semaglutide in Subjects With Non-cirrhotic Non-alcoholic Steatohepatitis Not yet recruiting NCT04822181 Phase 3 Semaglutide;Placebo
38 Clinical Trial to Evaluate the Efficacy of Metadoxine as a Therapy for Patients With Non-alcoholic Steatohepatitis Suspended NCT02541045 Phase 3 metadoxine
39 A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase III Study to Evaluate the Efficacy and Safety of Elafibranor in Patients With Nonalcoholic Steatohepatitis (NASH) and Fibrosis Terminated NCT02704403 Phase 3 Elafibranor;Placebo
40 Randomised, Double-Blind, Placebo-Controlled, Multi-Centre Study to Evaluate the Safety and Efficacy of Eltrombopag to Reduce the Need for Platelet Transfusion in Thrombocytopenic Subjects With Chronic Liver Disease Undergoing Elective Invasive Procedures Terminated NCT00678587 Phase 3 Eltrombopag;Placebo
41 AURORA: A Phase 3 Study to Evaluate the Efficacy and Safety of Cenicriviroc for the Treatment of Liver Fibrosis in Adult Subjects With Nonalcoholic Steatohepatitis Terminated NCT03028740 Phase 3 Cenicriviroc;Placebo
42 A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Selonsertib in Subjects With Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis (NASH) Terminated NCT03053063 Phase 3 SEL;Placebo to match SEL 6 mg;Placebo to match SEL 18 mg
43 A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Selonsertib in Subjects With Nonalcoholic Steatohepatitis (NASH) and Bridging (F3) Fibrosis Terminated NCT03053050 Phase 3 SEL;Placebo to match SEL 6 mg;Placebo to match SEL 18 mg
44 A Double-blind, Randomized, Placebo-controlled, Parallel Group Study of Rimonabant 20 mg Daily for the Treatment of Non-diabetic Patients With Nonalcoholic Steatohepatitis (NASH) Terminated NCT00576667 Phase 3 Rimonabant;Placebo (for Rimonabant)
45 A Double-blind, Randomized, Placebo-controlled, Parallel Group Study of Rimonabant 20 mg Daily for the Treatment of Type 2 Diabetic Patients With Nonalcoholic Steatohepatitis (NASH). Terminated NCT00577148 Phase 3 Rimonabant;Placebo (for Rimonabant)
46 A Randomized Controlled Project to Study the Efficacy of Combined Pentoxiphylline and Vitamin E Versus Vitamin E in Patients With Non- Alcoholic Steatohepatitis Withdrawn NCT01384578 Phase 3 pentoxiphylline and Vitamin E;Vitamin E
47 Rosiglitazone Versus Rosiglitazone and Metformin (Avandamet) Versus Combination Rosiglitazone and Losartan in the Treatment of Nonalcoholic Steatohepatitis (NASH). A Prospective, Open-Label, Randomized Trial Unknown status NCT00699036 Phase 2 avandia;metformin;losartan
48 Comparison the Effectiveness of L-Carnitine With Atorvastatin in Non-Alcoholic Steatohepatitis (NASH) Unknown status NCT01617772 Phase 2 Atorvastatin;L-Carnitine;Placebo
49 A Study to Assess ARI-3037MO on Hepatic Fat Metabolism in Patients With Dysglycemia and Evidence of Hepatic Steatosis Unknown status NCT02574325 Phase 2 Placebo;ARI-3037MO
50 A Phase 2, Multi-Center, Double-Blind, Randomized, Placebo-controlled Study of MGL-3196 in Patients With Non-alcoholic Steatohepatitis Unknown status NCT02912260 Phase 2 MGL-3196;Placebo

Search NIH Clinical Center for Visceral Steatosis

Genetic Tests for Visceral Steatosis

Anatomical Context for Visceral Steatosis

MalaCards organs/tissues related to Visceral Steatosis:

40
Liver, Endothelial, Skeletal Muscle, Hypothalamus, Brain, Heart

Publications for Visceral Steatosis

Articles related to Visceral Steatosis:

(show top 50) (show all 73)
# Title Authors PMID Year
1
Organic cation/carnitine transporter OCTN2 (Slc22a5) is responsible for carnitine transport across apical membranes of small intestinal epithelial cells in mouse. 61 54
16754783 2006
2
Expression and distribution of OCTN2 in mouse epididymis and its association with obstructive azoospermia in juvenile visceral steatosis mice. 61 54
16734862 2006
3
[Biopharmaceutical studies on molecular mechanisms of membrane transport]. 54 61
12510384 2002
4
A missense mutation of mouse OCTN2, a sodium-dependent carnitine cotransporter, in the juvenile visceral steatosis mouse. 54 61
9837751 1998
5
Sexual dimorphism of lipid metabolism in very long-chain acyl-CoA dehydrogenase deficient (VLCAD-/-) mice in response to medium-chain triglycerides (MCT). 61
25887160 2015
6
Hepatic toxicity of dronedarone in mice: role of mitochondrial β-oxidation. 61
24881592 2014
7
Carnitine is necessary to maintain the phenotype and function of brown adipose tissue. 61
21321536 2011
8
Induction of PDK4 in the heart muscle of JVS mice, an animal model of systemic carnitine deficiency, does not appear to reduce glucose utilization by the heart. 61
21190881 2011
9
[Study on the novel factors regulating mitochondrial dynamics]. 61
21048415 2010
10
Genetic deficiency of carnitine/organic cation transporter 2 (slc22a5) is associated with altered tissue distribution of its substrate pyrilamine in mice. 61
19821448 2009
11
Failure of the feeding response to fasting in carnitine-deficient juvenile visceral steatosis (JVS) mice: involvement of defective acyl-ghrelin secretion and enhanced corticotropin-releasing factor signaling in the hypothalamus. 61
19744557 2009
12
Carnitine/organic cation transporter OCTN2 (Slc22a5) is responsible for renal secretion of cephaloridine in mice. 61
19220985 2009
13
Toxicity of valproic acid in mice with decreased plasma and tissue carnitine stores. 61
17986647 2008
14
Effect of carnitine deprivation on carnitine homeostasis and energy metabolism in mice with systemic carnitine deficiency. 61
18417958 2008
15
Involvement of carnitine/organic cation transporter OCTN2 (SLC22A5) in distribution of its substrate carnitine to the heart. 61
18574325 2008
16
Spontaneous development of intestinal and colonic atrophy and inflammation in the carnitine-deficient jvs (OCTN2(-/-)) mice. 61
17884651 2007
17
Pressure overload-induced cardiomyopathy in heterozygous carrier mice of carnitine transporter gene mutation. 61
17664396 2007
18
Prolonged effect of single carnitine administration on fasted carnitine-deficient JVS mice regarding their locomotor activity and energy expenditure. 61
17027329 2006
19
Regulation of mitochondrial morphology and cell survival by Mitogenin I and mitochondrial single-stranded DNA binding protein. 61
16860483 2006
20
Combined therapy with PPARalpha agonist and L-carnitine rescues lipotoxic cardiomyopathy due to systemic carnitine deficiency. 61
16546150 2006
21
Fasting-induced reduction in locomotor activity and reduced response of orexin neurons in carnitine-deficient mice. 61
16540195 2006
22
Attenuation of cardiac hypertrophy in carnitine-deficient juvenile visceral steatosis (JVS) mice achieved by lowering dietary lipid. 61
16452314 2006
23
Dietary fish oil attenuates cardiac hypertrophy in lipotoxic cardiomyopathy due to systemic carnitine deficiency. 61
15963478 2005
24
Identification of the up- and down-regulated genes in the heart of juvenile visceral steatosis mice. 61
15056854 2004
25
Impact of alpha-tocopherol on cardiac hypertrophy due to energy metabolism disorder: the involvement of 1,2-diacylglycerol. 61
12798429 2003
26
Functional disorders of the oxidative phosphorylation system in the heart mitochondria of mice with juvenile visceral steatosis. 61
12612434 2003
27
Carnitine transport: pathophysiology and metabolism of known molecular defects. 61
12889657 2003
28
Changes in distinct species of 1,2-diacylglycerol in cardiac hypertrophy due to energy metabolic disorder. 61
12504818 2003
29
Hyperammonemia in carnitine-deficient adult JVS mice used by starvation. 61
12602512 2002
30
Novel mRNA molecules are induced in hypertrophied ventricles of carnitine-deficient mice and belong to a family of up-regulated gene in cells overexpressing c-erbB-2. 61
12359334 2002
31
Age-associated cardiomyopathy in heterozygous carrier mice of a pathological mutation of carnitine transporter gene, OCTN2. 61
12084797 2002
32
A heterozygote phenotype is present in the jvs +/- mutant mouse livers. 61
12175785 2002
33
Activities of cytochrome p450 enzymes in liver and kidney microsomes from systemic carnitine deficiency mice with a gene mutation of carnitine/organic cation transporter. 61
15618652 2002
34
Functional relevance of carnitine transporter OCTN2 to brain distribution of L-carnitine and acetyl-L-carnitine across the blood-brain barrier. 61
11739607 2001
35
Calcineurin inhibitor attenuates cardiac hypertrophy due to energy metabolic disorder. 61
11773940 2001
36
Antioxidant changes in the hypertrophied heart due to energy metabolic disorder. 61
11605989 2001
37
Carnitine transport by organic cation transporters and systemic carnitine deficiency. 61
11509010 2001
38
Effect of gamma-butyrobetaine on fatty liver in juvenile visceral steatosis mice. 61
11341370 2001
39
Molecular and physiological evidence for multifunctionality of carnitine/organic cation transporter OCTN2. 61
11160873 2001
40
Genomic organization and mapping of mouse CDV (carnitine deficiency-associated gene expressed in ventricle)-1 and its related CDV-1R gene. 61
11130971 2000
41
Antagonizing effect of AP-1 on glucocorticoid induction of urea cycle enzymes: a study of hyperammonemia in carnitine-deficient, juvenile visceral steatosis mice. 61
11136545 2000
42
The signaling pathway of cardiotrophin-1 is not activated in hypertrophied ventricles of carnitine-deficient juvenile visceral steatosis (JVS) mice. 61
10904873 2000
43
Involvement of a cis-acting element in the suppression of carbamoyl phosphate synthetase I gene expression in the liver of carnitine-deficient mice. 61
10562461 1999
44
Loss of wild-type carrier-mediated L-carnitine transport activity in hepatocytes of juvenile visceral steatosis mice. 61
10498652 1999
45
Decreased tissue distribution of L-carnitine in juvenile visceral steatosis mice. 61
10087008 1999
46
Dysfunctions of the epididymis as a result of primary carnitine deficiency in juvenile visceral steatosis mice. 61
10100867 1999
47
Primary systemic carnitine deficiency is caused by mutations in a gene encoding sodium ion-dependent carnitine transporter. 61
9916797 1999
48
Pyruvate dehydrogenase kinase 4 mRNA is increased in the hypertrophied ventricles of carnitine-deficient juvenile visceral steatosis (JVS) mice. 61
10609898 1999
49
Catecholamine metabolism inhibitors and receptor blockades only partially suppress cardiac hypertrophy of juvenile visceral steatosis mice with systemic carnitine deficiency. 61
10210276 1999
50
Cardiomegaly in the juvenile visceral steatosis (JVS) mouse is reduced with acute elevation of heart short-chain acyl-carnitine level after L-carnitine injection. 61
10025944 1999

Variations for Visceral Steatosis

Expression for Visceral Steatosis

Search GEO for disease gene expression data for Visceral Steatosis.

Pathways for Visceral Steatosis

GO Terms for Visceral Steatosis

Cellular components related to Visceral Steatosis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 mitochondrial outer membrane GO:0005741 8.62 CPT1B CPT1A

Biological processes related to Visceral Steatosis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 fatty acid metabolic process GO:0006631 9.26 CPT1B CPT1A
2 fatty acid beta-oxidation GO:0006635 9.16 CPT1B CPT1A
3 carnitine shuttle GO:0006853 8.96 CPT1B CPT1A
4 carnitine metabolic process GO:0009437 8.62 CPT1B CPT1A

Molecular functions related to Visceral Steatosis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 transferase activity, transferring acyl groups GO:0016746 8.96 CPT1B CPT1A
2 carnitine O-palmitoyltransferase activity GO:0004095 8.62 CPT1B CPT1A

Sources for Visceral Steatosis

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 20-May-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 Tocris
70 UMLS
71 UMLS via Orphanet
Content
Loading form....